Curriculum Vitaes
  1. Researcher Search Results
  2. Hasegawa Midori

Hasegawa Midori

  (長谷川 みどり)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
医学博士
J-GLOBAL ID
200901076209356036
researchmap Member ID
5000025129

Research Interests

 9

Research Areas

 1

Research History

 4

Education

 2

Committee Memberships

 2

Awards

 1

Papers

 117
  • Midori Hasegawa, Hiromichi Matsushita, Kensei Yahata, Akira Sugawara, Yoshitaka Ishibashi, Ryoko Kawahara, Yoshifumi Hamasaki, Hitoshi Kanno, Sachie Yamada, Norio Nii, Masao Kato, Atsushi Ohashi, Shigehisa Koide, Hiroki Hayashi, Yukio Yuzawa, Naotake Tsuboi
    Therapeutic Apheresis and Dialysis, 25(4) 407-414, Aug, 2021  
  • 多賀谷 知輝, 中島 颯之介, 中島 若菜, 堀内 雅人, 田中 友規, 成宮 利幸, 大山 翔也, 伊藤 辰将, 大谷内 樹那, 横江 優貴, 平野 恭子, 小出 滋久, 林 宏樹, 高橋 和男, 長谷川 みどり, 湯澤 由紀夫, 坪井 直毅
    日本透析医学会雑誌, 54(Suppl.1) 532-532, May, 2021  
  • 細江 眞生, 森 万佑子, 鈴木 むつみ, 山田 幸恵, 新 典雄, 加藤 政雄, 大高 洋平, 長谷川 みどり, 坪井 直毅, 中井 滋
    日本透析医学会雑誌, 54(Suppl.1) 557-557, May, 2021  
  • Midori Hasegawa, Jin Iwasaki, Satoshi Sugiyama, Takuma Ishihara, Yoshihiro Yamamoto, Hiroaki Asada, Shigehisa Koide, Hiroki Hayashi, Kazuo Takahashi, Daijo Inaguma, Yukio Yuzawa, Naotake Tsuboi
    PloS one, 16(1) e0245869, 2021  
    INTRODUCTION: Degenerative aortic valve stenosis (AS) is a chronic progressive disease that resembles atherosclerosis development. Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is reportedly associated with accelerated atherosclerosis. This study aimed to examine the development of AS in patients with myeloperoxidase-AAV (MPO-AAV) with renal involvement at more than 1 year after the onset of vasculitis. METHODS: We performed a retrospective review of clinical records of MPO-AAV patients with renal involvement without AS at the onset of vasculitis who were treated in three hospitals and three dialysis clinics. RESULTS: The study included 97 MPO-AAV patients with renal involvement and 230 control patients with chronic kidney disease (CKD). Among them, 64 patients had AS. The prevalence rates of AS were 28.9% and 15.7% in MPO-AAV and control patients, respectively (p = 0.006). The multivariable logistic regression analysis showed that MPO-AAV, dialysis dependence, and hypertension were independently associated factors for AS. In MPO-AAV patients, systolic blood pressure was positively significantly associated with AS, whereas glucocorticoid dose of induction therapy was negatively significantly associated. The use of cyclophosphamide tended to be negatively associated with AS. The survival rate was significantly lower for patients with AS than for those without AS. CONCLUSIONS: The AS prevalence rate was significantly higher in MPO-AAV patients at more than 1 year after the onset of vasculitis than in control CKD patients. Therefore, regular monitoring of echocardiography during MPO-AAV treatment is suggested.
  • Haruna Arai, Soshiro Ogata, Takaya Ozeki, Kazuo Takahashi, Naotake Tsuboi, Shoichi Maruyama, Daijo Inaguma, Midori Hasegawa, Yukio Yuzawa, Hiroki Hayashi
    Arthritis research & therapy, 22(1) 261-261, Nov 5, 2020  
    BACKGROUND: The present study aimed to investigate associations between long-term renal function, whether IgG4-related tubulointerstitial nephritis (TIN) was diagnosed by renal biopsy at initial examination, chronic kidney disease (CKD) stage, and histological stage in patients with IgG4-related TIN. METHODS: This study used a retrospective cohort design including almost all patients who underwent renal biopsy at Fujita Health University Hospital and Nagoya University or its affiliated hospitals in Aichi between April 2003 and March 2015 (n = 6977 renal biopsies). The primary outcome was longitudinal changes in eGFR. Main exposures were whether IgG4-related TIN was diagnosed by renal biopsy at the initial examination, CKD stage, and its histological stage. Linear mixed models were performed to examine associations. RESULTS: Of the 6977 samples, there were 24 patients (with 201 records due to repeated measures) with IgG4-related TIN (20 men, mean age, 68.7 ± 9.7 years). They were followed up 6.6 ± 2.8 years after the renal biopsy and underwent glucocorticoid treatment. We found significant increase in eGFR from the baseline to 2 and 6 months after treatment initiation, which was maintained until 60 months. Patients initially diagnosed with IgG4-related TIN had higher eGFR from the baseline (at the start of treatment) to 60 months than those who were not. Compared with patients with CKD stage 3, patients with CKD stages 4 and 5 had lower eGFR at the baseline and other time points. Patients with histological stage B had comparatively lower eGFR at each point than stage A patients. Those mean differences of eGFR were stable from the baseline to 60 months. CONCLUSIONS: After the treatment initiation, renal function rapidly improved and maintained for a long period, even with advanced CKD stage. We showed importance of early diagnosis of IgG4-related TIN in maintaining eGFR.
  • Ryosuke Umeda, Soshiro Ogata, Shigeo Hara, Kazuo Takahashi, Daijo Inaguma, Midori Hasegawa, Hidetaka Yasuoka, Yukio Yuzawa, Hiroki Hayashi, Naotake Tsuboi
    Arthritis research & therapy, 22(1) 260-260, Nov 4, 2020  
    BACKGROUND: Although the 2018 revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification was proposed recently, until now, no reports have been made comparing the association of renal prognosis between the 2018 revised ISN/RPS classification and the 2003 ISN/RPS classification. The present study aimed to assess the usefulness, especially of activity and chronicity assessment, of the 2018 revised ISN/RPS classification for lupus nephritis (LN) in terms of renal prognosis compared to the classification in 2003. METHODS: We retrospectively collected medical records of 170 LN patients from the database of renal biopsy at Fujita Health University from January 2003 to April 2019. Each renal biopsy specimen was reevaluated according to both the 2003 ISN/RPS classification and the 2018 revised ISN/RPS classification. Renal endpoint was defined as a 30% decline of estimated glomerular filtration rate (eGFR). RESULTS: A total of 129 patients were class III/IV±V (class III, 44 patients; class IV, 35 patients; class III/IV+V, 50 patients). The mean age was 42 years, 88% were female, and the median observation period was 50.5 months. Renal prognosis was significantly different among the classes and significantly poor in the patients with higher modified National Institute of Health (mNIH) chronicity index (C index, ≥ 4) by a log-rank test (p = 0.05 and p = 0.02, respectively). By Cox proportional hazard models, only the C index was significantly associated with renal outcome (hazard ratio 1.32, 95% CI 1.11-1.56, p ≤ 0.01), while the classes, the 2003 activity and chronicity subdivision, and the mNIH activity index had no significant association with renal outcome. Each component of the C index was significantly associated with renal outcome in different models. CONCLUSION: This study demonstrates that the 2018 revised ISN/RPS classification was more useful in terms of association with renal prognosis compared to the 2003 ISN/RPS classification.
  • Hiroyuki Yoshida, Daijo Inaguma, Eri Koshi-Ito, Soshiro Ogata, Akimitsu Kitagawa, Kazuo Takahashi, Shigehisa Koide, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa, Naotake Tsuboi
    Renal failure, 42(1) 646-655, Nov, 2020  Peer-reviewed
    INTRODUCTION: There are few studies on the association between serum uric acid (UA) level and mortality in incident dialysis patients. We aimed to clarify whether the serum UA level at dialysis initiation is associated with mortality during maintenance dialysis. METHODS: We enrolled 1486 incident dialysis patients who participated in a previous multicenter prospective cohort study in Japan. We classified the patients into the following five groups according to their serum UA levels at dialysis initiation: G1 with a serum UA level <6 mg/dL; G2, 6.0-8.0 mg/dL; G3, 8.0-10.0 mg/dL; G4, 10.0-12.0 mg/dL; and G5, ≥12.0 mg/dL. We created three models (Model 1: adjusted for age and sex, Model 2: adjusted for Model 1 + 12 variables, and Model 3: stepwise regression adjusted for Model 2 + 13 variables) and performed a multivariate Cox proportional hazard regression analysis to examine the association between the serum UA level and outcomes, including infection-related mortality. RESULTS: Hazard ratios (HRs) were calculated relative to the G2, because the all-cause mortality rate was the lowest in G2. For Models 1 and 2, the all-cause mortality rate was significantly higher in G5 than in G2 (HR: 1.63, 95% confidence interval [CI]: 1.14-2.33 and HR: 1.78, 95% CI: 1.19-2.68, respectively). For Models 1, 2, and 3, the infection-related mortality rate was significantly higher in G5 than in G2 (HR: 2.75, 95% CI: 1.37-5.54, HR: 3.09, 95% CI: 1.45-6.59, HR: 3.37, and 95% CI: 1.24-9.15, respectively). CONCLUSIONS: Extreme hyperuricemia (serum UA level ≥12.0 mg/dL) at dialysis initiation is a risk factor for infection-related deaths.
  • 吉田 浩之, 湯澤 由紀夫, 長谷川 みどり, 稲熊 大城, 坪井 直毅, 林 宏樹, 小出 滋久, 大山 翔也, 多賀谷 知輝, 伊藤 辰将, 成宮 利幸, 磯貝 理恵子, 古田 弘貴, 堀内 雅人
    腎と透析, 89(別冊 腹膜透析2020) 226-227, Aug, 2020  
  • Atsushi Ohashi, Shigeru Nakai, Hideo Hori, Sachie Yamada, Masao Kato, Shigehisa Koide, Hiroki Hayashi, Naotake Tsuboi, Daijo Inaguma, Midori Hasegawa, Yukio Yuzawa
    Therapeutic Apheresis and Dialysis, Jun 11, 2020  
  • Yukako Ohyama, Hisateru Yamaguchi, Kazuki Nakajima, Tomohiro Mizuno, Yukihiro Fukamachi, Yasuto Yokoi, Naotake Tsuboi, Daijo Inaguma, Midori Hasegawa, Matthew B Renfrow, Jan Novak, Yukio Yuzawa, Kazuo Takahashi
    Scientific reports, 10(1) 671-671, Jan 20, 2020  Peer-reviewed
    A common renal disease, immunoglobulin A (IgA) nephropathy (IgAN), is associated with glomerular deposition of IgA1-containing immune complexes. IgA1 hinge region (HR) has up to six clustered O-glycans consisting of Ser/Thr-linked N-acetylgalactosamine with β1,3-linked galactose and variable sialylation. IgA1 glycoforms with some galactose-deficient (Gd) HR O-glycans play a key role in IgAN pathogenesis. The clustered and variable O-glycans make the IgA1 glycomic analysis challenging and better approaches are needed. Here, we report a comprehensive analytical workflow for IgA1 HR O-glycoform analysis. We combined an automated quantitative analysis of the HR O-glycopeptide profiles with sequential deglycosylation to remove all but Gd O-glycans from the HR. The workflow was tested using serum IgA1 from healthy subjects. Twelve variants of glycopeptides corresponding to the HR with three to six O-glycans were detected; nine glycopeptides carried up to three Gd O-glycans. Sites with Gd O-glycans were unambiguously identified by electron-transfer/higher-energy collision dissociation tandem mass spectrometry. Extracted ion chromatograms of isomeric glycoforms enabled quantitative assignment of Gd sites. The most frequent Gd site was T236, followed by S230, T233, T228, and S232. The new workflow for quantitative profiling of IgA1 HR O-glycoforms with site-specific resolution will enable identification of pathogenic IgA1 HR O-glycoforms in IgAN.
  • 大橋 篤, 中井 滋, 堀 秀生, 山田 幸恵, 加藤 政雄, 小出 滋久, 稲熊 大城, 長谷川 みどり, 湯澤 由紀夫
    日本アフェレシス学会雑誌, 38(Suppl.) 203-203, Oct, 2019  
  • Koide S, Inaguma D, Koshi-Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y
    Clinical nephrology, 92(4) 180-189, Oct, 2019  Peer-reviewed
  • 吉野 寧維, 平塚 いづみ, 四馬田 恵, 伊藤 泰平, 佐々木 ひとみ, 長谷川 みどり, 日下 守, 白木 良一, 剣持 敬, 鈴木 敦詞
    日本骨粗鬆症学会雑誌, 5(Suppl.1) 290-290, Sep, 2019  
  • Ito T, Kenmochi T, Aida N, Kurihara K, Kawai A, Suzuki A, Shibata M, Hiratsuka I, Hasegawa M
    Journal of clinical medicine, 8(9), Sep, 2019  Peer-reviewed
  • Maya Fujii, Daijo Inaguma, Shigehisa Koide, Eri Ito, Kazuo Takahashi, Hiroki Hayashi, Naotake Tsuboi, Midori Hasegawa, Yukio Yuzawa
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 23(4) 353-361, Aug, 2019  Peer-reviewed
    Hypertension is common in patients with chronic kidney disease. Whether blood pressure management before dialysis initiation influences prognosis during maintenance dialysis remains unclear. Hence, we surveyed the status of antihypertensive drug use in incident dialysis patients. Moreover, we examined the association between antihypertensive drug use patterns at the time of dialysis initiation and mortality. We used a database derived from the multicenter prospective Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis, which included 1520 incident dialysis patients in Aichi prefecture, Japan. The baseline in the present study was set as the time of dialysis initiation. We examined antihypertensive drug prescription patterns at baseline, as well as the association between use of antihypertensive drugs and mortality after dialysis initiation. Among all participants, 1440 were taking at least one antihypertensive drug. The rate of calcium channel blocker (CCB) use was highest, accounting for 74.3%. CCB use was significantly associated with lower all-cause and cardiovascular-related mortality (hazard ratio [HR]: 0.62 and 0.57, 95% confidence interval [CI]: 0.46-0.85 and [0.35-0.91], respectively). Compared with no use of either drug, combination therapy with a renin angiotensin system blocker (RASB) and CCB was significantly associated with lower mortality (HR: 0.51, 95% CI: 0.34-0.76). The present study demonstrated that antihypertensive drugs were used in 95% of incident dialysis patients. In addition, use of a CCB and combination therapy with a CCB and RASB at the time of dialysis initiation was associated with lower mortality during maintenance dialysis.
  • Koide S, Inaguma D, Koshi-Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y
    26, Jul, 2019  Peer-reviewed
  • Ohyama Yukako, Takahashi Kazuo, Yamaguchi Hisateru, Matsushita Shoko, Nakajima Kazuki, Tsuboi Notake, Daijo Inaguma, Midori Hasegawa, Renfrow Matthew B, Novak Jan, Hiki Yoshiyuki, Yukio Yuzawa
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 34 111, Jun, 2019  Peer-reviewed
  • Ohashi A, Nakai S, Yamada S, Kato M, Hasegawa M
    Ther Apher Dial., 23(3) 242-247, Jun, 2019  Peer-reviewed
  • Kojima M, Inaguma D, Koide S, Koshi-Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y
    Nephron., 11(1) 1-11, Jun, 2019  Peer-reviewed
  • Sachie Yamada, Midori Hasegawa, Norio Nii, Masao Kato, Atsushi Ohashi, Ryota Suzuki, Masakazu Komatsu, Kosei Abe, Yosuke Hata, Kazuo Takahashi, Hiroki Hayashi, Shigehisa Koide, Naotake Tsuboi, Daijo Inaguma, Yukio Yuzawa
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 23(3) 237-241, Jun, 2019  Peer-reviewed
    Cell-free and concentrated ascites reinfusion therapy (CART) by internal filtration pressure method (internal method) and external filtration pressure method (external method) using the same cancerous ascites was performed. The rate of rise in circuit pressure and recovered components were compared between the two methods. The factors related to circuit pressure rise were also researched. In both methods, circuit pressure rose in 50% of cases. The recovery rates of IgG, IgA, IgM, and haptoglobin were significantly higher for the internal method than for the external method, whereas the recovery rate of α1 -antitrypsin was significantly lower in the internal method than in the external method. The levels of IL-6, haptoglobin, α1 -antitrypsin, and fibrinogen/fibrindegradation products (FDP) in the original ascites were significantly higher in the group wherein circuit pressure rose than in that without circuit pressure rise. These proteins might be related to the rise in circuit pressure.
  • Kojima M, Inaguma D, Koide S, Koshi-Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y
    Nephron, 143(1) 43-53, 2019  Peer-reviewed
  • Inaguma D, Morii D, Kabata D, Yoshida H, Tanaka A, Koshi-Ito E, Takahashi K, Hayashi H, Koide S, Tsuboi N, Hasegawa M, Shintani A, Yuzawa Y
    PloS one, 14(8) e0221352, 2019  Peer-reviewed
  • Okada Hirokazu, Yasuda Yoshinari, Kashihara Naoki, Asahi Koichi, Ito Takafumi, Kaname Shinya, Kanda Eiichiro, Kanno Yoshihiko, Shikata Kenichi, Shibagaki Yugo, Tsuchiya Ken, Tsuruya Kazuhiko, Nagata Daisuke, Narita Ichiei, Nangaku Masaomi, Hattori Motoshi, Hamano Takayuki, Fujimoto Shouichi, Moriyama Toshiki, Yamagata Kunihiro, Yamamoto Ryohei, Wakasugi Minako, Ashida Akira, Usui Joichi, Kawamura Kazuko, Kitamura Kenichiro, Konta Tsuneo, Suzuki Yusuke, Tsuruoka Shuichi, Nishio Saori, Fujii Naohiko, Fujii Hideki, Wada Takehiko, Yokoyama Hitoshi, Aoki Katsunori, Akiyama Daiichiro, Araki Shin-ichi, Arima Hisatomi, Ishikawa Eiji, Ishikura Kenji, Ishizuka Kiyonobu, Ishimoto Takuji, Ishimoto Yu, Iseki Kunitoshi, Itabashi Mitsuyo, Ichioka Satoko, Ichikawa Kazunobu, Ichikawa Daisuke, Inoue Shuji, Imai Toshimi, Imamura Hideaki, Iwata Yasunori, Iwazu Yoshitaka, Usui Toshiaki, Uchida Keiko, Egawa Masahiro, Ohara Shinichiro, Omori Norio, Okada Rieko, Okuda Yusuke, Ozeki Takaya, Obata Yoko, Kai Hirayasu, Kato Noritoshi, Kanasaki Keizo, Kaneko Yoshikatsu, Kabasawa Hideyuki, Kawaguchi Takehiko, Kawasaki Yukihiko, Kawashima Keisuke, Kawano Haruna, Kikuchi Kan, Kihara Masao, Kimura Yoshiki, Kurita Noriaki, Koike Kentaro, Koizumi Masahiro, Kojima Chiari, Goto Shunsuke, Konomoto Takao, Kohagura Kentaro, Komatsu Hiroyuki, Komaba Hirotaka, Saito Chie, Sakai Yukinao, Sakaguchi Yusuke, Satonaka Hiroshi, Jimi Kanako, Shimizu Akihiro, Shimizu Sayaka, Shirai Sayuri, Shinzawa Maki, Sugiyama Kazuhiro, Suzuki Tomo, Suzuki Hitoshi, Suyama Kazuhide, Segawa Hiroyoshi, Takahashi Kazuya, Tanaka Kenichi, Tanaka Tetsuhiro, Tsunoda Ryoya, Tsuruta Yuki, Nakakura Hyogo, Nagasawa Yasuyuki, Nakanishi Koichi, Nagahama Masahiko, Nakaya Izaya, Nanami Masayoshi, Niihata Kakuya, Nishi Shinichi, Nishiwaki Hiroki, Hasegawa Shoko, Hasegawa Midori, Hanada Ken, Hayashi Hiroki, Harada Ryoko, Hishida Manabu, Hirano Daishi, Hirahashi Junichi, Hirama Akio, Hirayama Kouichi, Fukagawa Masafumi, Fukuda Akihiro, Fujii Yoshiyuki, Fujisaki Kiichiro, Furuya Fumihiko, Hoshino Junichi, Hosojima Michihiro, Honda Kenjiro, Masuda Takahiro, Matsui Kosuke, Matsukuma Yuta, Matsumura Hideki, Mii Akiko, Miura Kenichiro, Mitobe Michihiro, Miyasato Yoshikazu, Miyamoto Satoshi, Miwa Saori, Yazawa Masahiko, Yata Yusuke, Yamamoto Yoshihiro, Watanabe Kimio, Japanese Society of Nephrology, Committee of Evidence-based Practice Guideline for the Treatment of CKD 2018, Evidence-based Practice Guideline for the Treatment of CKD Production Group(Work group)
    Clinical and Experimental Nephrology, 23(1) 1-15, Jan, 2019  Peer-reviewed
  • Nobuya Kitaguchi, Harutsugu Tatebe, Kazuyoshi Sakai, Kazunori Kawaguchi, Shinji Matsunaga, Tomoko Kitajima, Hiroshi Tomizawa, Masao Kato, Satoshi Sugiyama, Nobuo Suzuki, Masao Mizuno, Hajime Takechi, Shigeru Nakai, Yoshiyuki Hiki, Hiroko Kushimoto, Midori Hasegawa, Yukio Yuzawa, Takahiko Tokuda
    Journal of Alzheimer's disease : JAD, 69(3) 687-707, 2019  Peer-reviewed
    The accumulation of amyloid-β protein (Aβ) and tau in the brain is a major pathological change related to Alzheimer's disease. We have continued to develop Extracorporeal Blood Aβ Removal Systems (E-BARS) as a method for enhancing Aβ clearance from the brain. Our previous report revealed that dialyzers effectively remove blood Aβ and evoke large Aβ influxes into the blood, resulting in a decrease in brain Aβ accumulation after initiating hemodialysis, and that patients who underwent hemodialysis had lower brain Aβ accumulation than those who did not. Here, plasma total tau concentrations from 30 patients undergoing hemodialysis were measured using an ultrasensitive immunoassay and compared to those from 11 age-matched controls. Plasma total tau concentrations were higher in patients with renal failure regardless of whether they underwent hemodialysis, suggesting the involvement of the kidneys in tau degradation and excretion. Hemodialyzers effectively removed blood Aβ but not extracorporeal blood tau. The influx of tau into the blood was observed at around the 1 h period during hemodialysis sessions. However, the influx amount of tau was far smaller than that of Aβ. Furthermore, histopathological analysis revealed similar, not significantly less, cerebral cortex phosphorylated tau accumulation between the 17 patients who underwent hemodialysis and the 16 age-matched subjects who did not, although both groups showed sparse accumulation. These findings suggest that hemodialysis may induce both tau and Aβ migration into the blood. However, as a therapeutic strategy for Alzheimer's disease, it may only be effective for removing Aβ from the brain.
  • Eri Ito, Daijo Inaguma, Shigehisa Koide, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
    Clinical and experimental nephrology, 22(6) 1309-1314, Dec, 2018  Peer-reviewed
    BACKGROUND: Whether vitamin D receptor activator (VDRA) use is beneficial in chronic kidney disease (CKD) is unclear, because it is possible that VDRA increases serum fibroblast growth factor 23 (FGF23) levels. We will conduct a randomized controlled trial in predialysis patients to determine the effect of VDRA alone or in combination with lanthanum carbonate (LC) on serum FGF23 levels. METHODS: This is a single-center, open-label, randomized controlled trial. Enrollment will commence February 1, 2018, using the following inclusion criteria: (1) age ≥ 20 years, (2) CKD with an estimated glomerular filtration rate of 10-45 mL/min/1.73 m2, (3) serum adjusted calcium level < 9.5 mg/dL, (4) serum phosphate level 4.0-6.0 mg/dL, and (5) serum intact parathyroid hormone (PTH) level ≥ 60 pg/mL. Study patients will be randomized 1:1 to receive alfacalcidol alone or in combination with LC. The initial dose of alfacalcidol will be 0.25-0.5 µg once a day according to serum adjusted calcium level. The initial dose of LC will be 250 mg once a day. We will measure serum intact and C-terminal FGF23 at 0, 4, 8, 12, 24, and 52 weeks. The primary outcome will be serum FGF23 level at 24 weeks compared with baseline. DISCUSSION: This study aims to determine whether low-dose oral VDRA increases serum FGF23 level and whether the combination of VDRA and LC inhibits this increase. The results will be useful in the management of CKD-mineral and bone disorder in predialysis patients. TRIAL REGISTRATION: UMIN000030503. Registered 20 January 2018.
  • Daijo Inaguma, Eri Ito, Kazuo Takahashi, Hiroki Hayashi, Shigehisa Koide, Midori Hasegawa, Yukio Yuzawa
    Clinical and experimental nephrology, 22(6) 1360-1370, Dec, 2018  Peer-reviewed
    INTRODUCTION: An increasing number of patients worldwide require dialysis as a result of hypertensive nephrosclerosis (HTN). However, in Japan, mortality in patients with end-stage renal disease (ESRD) has not been well by primary kidney disease including HTN and diabetic nephropathy (DN). Hence, we examined the differences in mortality among the primary kidney diseases of incident dialysis patients. METHODS: The study was a multicenter prospective cohort analysis including 1520 incident dialysis patients in Aichi prefecture, Japan. We classified patients into three groups according to the primary kidney disease [i.e., a HTN group, n = 384, a DN group n = 658, and a chronic glomerulonephritis (CGN) group, n = 224]. In addition, we classified patients into the HTN group and the DN group using propensity score matching. We compared outcomes including all-cause and infection-related mortality. RESULTS: The mortality rates of the HTN, the DN, and the CGN group, were 135.9, 64.2, and 34.8 per 1000 patient years, respectively. All-cause mortality and infection-related mortality rates in the HTN group were as high as those in the DN group after adjustment for age, gender, history of cardiovascular disease, and estimated glomerular filtration rate. No significant difference of all-cause mortality was observed after propensity score matching between the two groups (Logrank test: p = 0.523). CONCLUSIONS: The present study was Japan's first large-scale prospective cohort to demonstrate that HTN is the second most common cause of ESRD. In addition, the prognosis of patients with HTN was as poor as that of patients with DN.
  • Haruna Arai, Hiroki Hayashi, Soshiro Ogata, Kenichi Uto, Jun Saegusa, Kazuo Takahashi, Shigehisa Koide, Daijyo Inaguma, Midori Hasegawa, Yukio Yuzawa
    Medicine, 97(51) e13545, Dec, 2018  Peer-reviewed
    RATIONALE: Immunoglobulin G4 related disease (IgG4-RD) rarely coexists with other autoimmune diseases, though we had a patient whose primary clinical problem was shifted from IgG4-RD to systemic lupus erythematosus (SLE) after gastrectomy. The present paper aimed to report pathological findings and clinical course of the patient. PATIENT CONCERNS: The patient was a male aged 74 years old with gastric cancer characterized by the following symptoms: Raynaud phenomenon, polyarthralgia, and swollen parotid glands on both sides. Before gastrectomy, laboratory examination results showed renal dysfunction, hypocomplementemia, antinuclear antibodies (ANAs) positivity, and elevated serum IgG and IgG4 levels. DIAGNOSIS: Based on postoperative renal biopsy showing severe plasma cell infiltration with tubulointerstitial fibrosclerosis, the patient was diagnosed with IgG4-RD. Despite significant improvement in renal function and reduction in parotid gland swelling during the postoperative follow-up period, after 7 months of the gastrectomy, anti-DNA antibody levels were increased and serositis was detected, which indicated the onset of SLE. IgG4-type ANA were also detected in the sera of the patient. INTERVENTIONS: Treatment by oral prednisolone at 30 mg/day was initiated. OUTCOMES: Pericardial fluid, pleural effusions, and thickening of the gallbladder wall improved after 3 months of treatment according to computed tomography. LESSONS: This study presented a rare case of comorbidity, wherein the patient's primary problem progressed from IgG4-type ANA-positive IgG4-RD to SLE after excision of gastric cancer.
  • Akiko Owaki, Daijo Inaguma, Isao Aoyama, Shinichiro Inaba, Shigehisa Koide, Eri Ito, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
    Renal failure, 40(1) 475-482, Nov, 2018  Peer-reviewed
    INTRODUCTION: As glomerular filtration rate (GFR) decreases, serum phosphate level increases. Previous reports indicated that serum phosphate level was associated with mortality in patients on dialysis. However, few reports have examined the association using dialysis initiation as the baseline period. METHODS: This was a multicenter prospective cohort analysis including 1492 patients. Patients were classified into four quartiles based on the serum phosphate level at dialysis initiation, with Q1 being the lowest and Q4 the highest. All-cause mortality after dialysis initiation was compared using the log-rank test. The propensity score represented the probability of being assigned to group Q1 or Q2-4. All-cause mortality was compared in propensity score-matched patients by using the log-rank test for Kaplan-Meier curves. All-cause mortality of Q1 was compared with that for Q2-4 using multivariate Cox proportional hazard regression analysis. All-cause mortality was also determined among stratified groups with or without use of phosphate binders. RESULTS: Significant differences in cumulative survival rates were observed between the four groups (p < .001). After propensity score-matching, mortality was significantly higher in the Q1 group than the Q2-4 group (p = .046). All-cause mortality was significantly higher in the Q1 group after adjustment for history of CAD (hazard ratio [HR] = 0.76, 95% confidence interval [CI]: 0.58 - 1.00, p = .048). However, there was no significant difference between the two groups after adjustment for estimated GFR. CONCLUSION: The serum phosphate level at the time of dialysis initiation was associated with all-cause mortality. However, the serum phosphate level was dependent on the renal function.
  • Kitaguchi N, Kato T, Matsunaga S, Hirano K, Iwata K, Kawaguchi K, Fujita K, Takechi H, Hasegawa M, Yuzawa Y, Ito K
    Neuropsychiatr Dis Treat., Nov 1;(14) 2931-2937, Nov, 2018  Peer-reviewed
  • 佐々木 ひと美, 日下 守, 高原 健, 市野 学, 深見 直彦, 白木 良一, 長谷川 みどり, 伊藤 泰平, 剣持 敬
    移植, 53(総会臨時) 325-325, Sep, 2018  
  • Nobuya Kitaguchi, Kazunori Kawaguchi, Kazunori Yamazaki, Hiroshi Kawachi, Miwa Sakata, Megumi Kaneko, Masao Kato, Kazuyoshi Sakai, Norimi Ohashi, Midori Hasegawa, Yoshiyuki Hiki, Yukio Yuzawa
    Journal of Artificial Organs, 21(2) 220-229, Jun 1, 2018  Peer-reviewed
    Accumulation of amyloid-β protein (Aβ) in the brain causes cognitive impairment in Alzheimer’s disease. We hypothesized that an extracorporeal system that rapidly removed Aβ from the blood may accelerate Aβ drainage from the brain. We previously reported that dialyzers remove blood Aβs effectively, mainly by adsorption on the inner surfaces of the hollow fibers, resulting in lower Aβ accumulation in the brains of patients undergoing hemodialysis than the controls without hemodialysis. The aim of the present study was to create a more convenient and effective blood Aβ removal system using adsorptive filtration, in which the filtrate returned to the body. Filtration from inside to outside of the fibers may enhance the adsorption of plasma Aβs on the surface of micropores inside the hollow fiber walls. Hence, pool solutions of 4 ng/mL synthetic Aβ1–40 and Aβ1–42 peptides (300 mL) or human plasma (1000 mL of 250–346 pg/mL Aβ1–40 and 30–48 pg/mL Aβ1–42) were circulated through polysulfone dialyzers at a flow rate of 50 mL/min to evaluate an adsorptive filtration system. The rates of Aβ reduction from the pool solutions significantly increased along with the filtration rates. A filtration rate of &gt 1 mL/min, preferably 5–10 mL/min resulted in an 80–100% reduction of Aβs within 30 min of circulation. The rates of Aβs passing through the membrane walls were maintained around 0% for plasma Aβs during circulation. Thus, our adsorptive filtration systems may be useful for removing blood Aβs for patients with Alzheimer’s disease.
  • Daijo Inaguma, Shigehisa Koide, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
    Nephrology (Carlton, Vic.), 23(5) 461-468, May, 2018  Peer-reviewed
    AIM: Some observational studies of the general population showed that resting heart rate was associated with mortality. However, the relationship was unclear in dialysis patients. METHODS: The study was a multicentre prospective cohort analysis including 1102 patients. Patients were classified into four groups based on resting heart rate just before starting the first dialysis session: <60/min; 60-79/min; 80-100/min; and ≥101/min. All-cause mortality, cardiovascular (CV) related mortality, and incidences of CV events after dialysis initiation were compared using the log-rank test. All-cause mortality rates for patients with heart rates <60, 60-79, and ≥101/min were compared to those for patients with heart rates 80-100/min, using multivariate Cox proportional hazard regression analysis. Moreover, we compared the outcomes among patients without use of β-blocker or heart failure symptom at the first dialysis session. RESULTS: Significant differences were observed in the all-cause mortality rates among the four groups (P = 0.007). Multivariate analysis revealed that all-cause mortality was significantly higher in patients with heart rate ≥ 101/min than in patients with heart rate 80-100/min (hazard ratio [HR] = 2.30, 95% confidence interval [CI]: 1.25-4.23). Subgroup analysis showed that among patients without use of b-blocker or heart failure symptom, all-cause mortality rates for those with heart rates ≥101/min were significantly higher than in patients with heart rate 80-100/min (HR = 2.98, 95% CI: 1.51-5.88, HR = 3.65, 95% CI: 1.59-8.36, respectively). CONCLUSION: The resting heart rate just before starting the first dialysis session was associated with all-cause mortality after dialysis initiation.
  • Aida N, Kenmochi T, Ito T, Nishikawa T, Hiratsuka I, Shibata M, Suzuki A, Hasegawa M, Kawai A, Kusaka M, Hoshinaga K, Matsubara H
    Pancreas., 47(5) 617-624, May, 2018  Peer-reviewed
  • Daijo Inaguma, Yuji Sasakawa, Noriko Suzuki, Eri Ito, Kazuo Takahashi, Hiroki Hayashi, Shigehisa Koide, Midori Hasegawa, Yukio Yuzawa
    BMC nephrology, 19(1) 80-80, Apr 3, 2018  Peer-reviewed
    BACKGROUND: Aortic stenosis (AS) is common in patients on dialysis as well as in the general population. AS leads to difficulty with dialysis therapy because of unstable conditions such as intradialytic hypotension due to low cardiac output. However, the precise morbidity rates and risk factors of AS in patients on dialysis are unknown. Moreover, there are no large-scale observational studies regarding the association between AS in patients on dialysis and mortality. Therefore, we will investigate whether morbidity of AS in patients on dialysis is associated with mortality. METHODS: This is a multicenter prospective cohort analysis in the Tokai region of Japan. The 75 participating centers in this study will enroll approximately 2400 patients during 12 months, with or without AS. We started enrollment in July 2017 and will follow patents until June 2023. Transthoracic echocardiography will be performed to evaluate aortic valve. Parameters used for evaluation of aortic valve are mean pressure gradient between left ventricle and ascending aorta, aortic valve area, and maximum aortic jet velocity. We will diagnose AS using the criteria based on the 2014 American Heart Association/ American College of Cardiology Guideline. We will also perform transthoracic echocardiography at 12, 24, 36, 48, and 60 months. Survival prognosis and CV events will be determined at the end of June 2019, 2020, 2021, 2022, and 2023. Development of AS will be also evaluated as new onset or annual change in AS parameters. We will classify patients based on the presence or absence of AS and the stages of AS and will compare outcomes. Study outcomes will include the following: 1) all-cause mortality rates; 2) incidence of cardiovascular (CV) events; 3) CV-related mortality rates; 4) infection-related mortality rates; 5) new onset or development of AS. DISCUSSION: We will consider the following hypotheses in this study, among others: The prevalence of AS is higher in dialysis patients; new onset and development of AS are associated with factors that are specific for dialysis, such as hyperphosphatemia, hyperparathyroidism, and medication; and outcomes in AS patients are poorer than in patients without AS at baseline. TRIAL REGISTRATION: UMIN000026756 , Registered March 29 2017.
  • 大山 友香子, 高橋 和男, 山口 央輝, 松下 祥子, 中嶋 和紀, 林 宏樹, 小出 滋久, 稲熊 大城, 長谷川 みどり, 比企 能之, 湯澤 由紀夫
    日本腎臓学会誌, 60(3) 364-364, Apr, 2018  Peer-reviewed
  • Daijo Inaguma, Shigehisa Koide, Eri Ito, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
    Clinical and experimental nephrology, 22(2) 353-364, Apr, 2018  Peer-reviewed
    BACKGROUND: Some studies have shown that the estimated glomerular filtration rate (eGFR) at the time of initiating dialysis was associated with mortality. However, the relationship between ratio of blood urea nitrogen to serum creatinine (BUN/Cr) and mortality is unknown. METHODS: The study was a multicenter, prospective cohort analysis including 1520 patients. Patients were classified into four quartiles based on the BUN/Cr ratio at the dialysis initiation, with Q1 having the lowest ratio and Q4 the highest. All-cause mortality after initiating dialysis was compared using the log-rank test. All-cause mortality of Q1, Q2, and Q3 was compared with that of Q4 using multivariate Cox proportional hazard regression analysis. Moreover, we compared the renal parameters including BUN/Cr ratio, eGFR, and creatinine clearance for sensitivity and specificity using receiver operative characteristic (ROC) curve. RESULTS: Significant differences were observed in all-cause mortality among the four groups (p < 0.001). Multivariate analysis revealed that all-cause mortality was significantly higher in Q4 than in Q1 [hazard ratio (HR) = 1.82, 95% confidence interval (CI) 1.24-2.67, p = 0.002]. The increase in BUN/Cr ratio was positively associated with mortality (HR 1.04, 95% CI 1.02-1.06, p = 0.002). The sensitivity and specificity of BUN/Cr ratio for 180, 365, 730, and 1095 days mortality ranged between 0.60-0.72 and 0.59-0.71, respectively. The area under the curve of BUN/Cr for all-cause mortality was the highest among the renal parameters. CONCLUSION: The BUN/Cr ratio at the time of initiation of dialysis was associated with all-cause mortality.
  • Ayako Kondo, Kazuo Takahashi, Hisateru Yamaguchi, Yuri Yoshida, Tomohiro Mizuno, Kazuki Nakajima, Hiroki Hayashi, Shigehisa Koide, Daijo Inaguma, Midori Hasegawa, Yoshiyuki Hiki, Yukio Yuzawa
    Fujita Medical Journal, 4(2) 36-41, 2018  Peer-reviewed
  • Daijo Inaguma, Eri Ito, Shigehisa Koide, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
    CARDIORENAL MEDICINE, 8(1) 71-81, 2018  Peer-reviewed
    Background: Several human studies reported that the combined use of renin-angiotensin system blockers (RASBs) and vitamin D receptor activators (VDRAs) resulted in decreased urinary protein excretion. However, it is unknown whether this combination therapy influences the incidence of cardiovascular (CV) events in dialysis patients. Methods: The study was a multicenter nonrandomized prospective cohort analysis including 1,518 patients. Patients were classified into 4 groups based on medications prescribed before dialysis initiation: those who did not receive RASBs or oral VDRAs (N group), those receiving only RASBs, those receiving only VDRAs, and those receiving a combination of RASBs and VDRAs (RD group). CV events after dialysis initiation were compared using the log-rank test. Factors contributing to the incidence of CV events were examined using multivariate Cox proportional hazard regression analysis. Results: Significant differences were observed in the incidence of CV events and all-cause mortality between the 4 groups (p = 0.021 and p = 0.001, respectively). Cox proportional hazard analysis revealed that the incidence of CV events was significantly lower in the RD group than in the N group (hazard ratio [HR] = 0.65, 95% confidence interval [CI]: 0.50-0.86, p = 0.002). Multivariate analysis revealed that the incidence of CV events was significantly lower in the RD group than in the N group (HR = 0.66, 95% CI: 0.47-0.93, p = 0.016). Conclusion: Combination therapy with RASBs and VDRAs in patients before dialysis initiation was associated with a reduction in CV events during maintenance dialysis. (C) 2017 S. Karger AG, Basel
  • 佐々木 ひと美, 日下 守, 深見 直彦, 河合 昭浩, 星長 清隆, 白木 良一, 布施 郁子, 長谷川 みどり, 伊藤 泰平, 剣持 敬
    移植, 52(総会臨時) 248-248, Aug, 2017  
  • 佐々木 ひと美, 市野 学, 河合 昭浩, 深見 直彦, 日下 守, 星長 清隆, 白木 良一, 長谷川 みどり, 伊藤 泰平, 剣持 敬
    移植, 52(総会臨時) 313-313, Aug, 2017  
  • Ryunosuke Okuyama, Junnichi Ishii, Hiroshi Takahashi, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Sadako Motoyama, Shigeru Matsui, Hiroyuki Naruse, Masayoshi Sarai, Midori Hasegawa, Eiichi Watanabe, Atsushi Suzuki, Mutsuharu Hayashi, Hideo Izawa, Yukio Yuzawa, Yukio Ozaki
    HEART AND VESSELS, 32(7) 880-892, Jul, 2017  Peer-reviewed
    Additional risk stratification may provide more aggressive and focalized preventive treatment to high-risk hypertensive patients according to the Japanese hypertension guidelines. We prospectively investigated the predictive value of high-sensitivity troponin I (hsTnI), both independently and in combination with N-terminal pro-B-type natriuretic peptide (NT-proBNP), for incident heart failure (HF) in high-risk hypertensive patients with preserved left ventricular ejection fraction (LVEF). Baseline hsTnI and NT-proBNP levels and echocardiography data were obtained for 493 Japanese hypertensive outpatients (mean age, 68.5 years) with LVEF ae&lt;yen&gt; 50%, no symptomatic HF, and at least one of the following comorbidities: stage 3-4 chronic kidney disease, diabetes mellitus, and stable coronary artery disease. During a mean follow-up period of 86.1 months, 44 HF admissions occurred, including 31 for HF with preserved ejection fraction (HFpEF) and 13 for HF with reduced ejection fraction (HFrEF; LVEF &lt; 50%). Both hsTnI (p &lt; 0.01) and NT-proBNP (p &lt; 0.005) levels were significant independent predictors of HF admission. Furthermore, when the patients were stratified into 4 groups according to increased hsTnI (ae&lt;yen&gt;highest tertile value of 10.6 pg/ml) and/or increased NT-proBNP (ae&lt;yen&gt;highest tertile value of 239.7 pg/ml), the adjusted relative risks for patients with increased levels of both biomarkers versus neither biomarker were 13.5 for HF admission (p &lt; 0.0001), 9.45 for HFpEF (p = 0.0009), and 23.2 for HFrEF (p = 0.003). Finally, the combined use of hsTnI and NT-proBNP enhanced the C-index (p &lt; 0.05), net reclassification improvement (p = 0.0001), and integrated discrimination improvement (p &lt; 0.05) to a greater extent than that of any single biomarker. The combination of hsTnI and NT-proBNP, which are individually independently predictive of HF admission, could improve predictions of incident HF in high-risk hypertensive patients but could not predict future HF phenotypes.
  • Inaguma D, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y
    BMC Nephrol., 18(1) 79, Mar, 2017  Peer-reviewed
  • Iwasaki Jin, Hasegawa Midori, Takahashi Kazuo, Hayashi Hiroki, Koide Shigehisa, Inaguma Daijyo, Yuzawa Yukio
    Fujita Medical Journal, 3(4) 97-100, 2017  
    <p>Background: Cell-free and concentrated ascites reinfusion therapy (CART) was approved by the National Insurance Scheme in 1981 in Japan and has since been used as a treatment modality for refractory ascites. Two filtration methods may be used for CART: the internal and external pressure filtration methods. However, the precise characteristics of each method are unknown.</p><p>Methods: Ascitic fluid will be obtained by puncture from patients with refractory cancerous ascites. The quantity of fluid obtained from each patient will be divided in half, and each half will be processed using either the internal or external pressure filtration method. The primary endpoint will be the time required for the transmembrane pressure to reach 500 mmHg. The secondary endpoints will be serial changes in the weight of the ascitic and filtered fluid, serial changes in the pressure at the inlet and outlet of the filter, measurement of the components of the ascitic and filtered fluid, and observation of the filter by visual inspection and light and electron microscopy.</p><p>Conclusion: This trial may clarify the characteristics of the two filtration methods.</p><p>Trial registration: UMIN000025382.</p>
  • Okuyama Ryunosuke, Ishii Junnichi, Takahashi Hiroshi, Kawai Hidek, Takashi Takashi, Harada Masahide, Yamada Akira, Motoyama Sadako, Matsui Shigeru, Naruse Hiroyuki, Hayashi Mutsuharu, Sarai Masayoshi, Hasegawa Midori, Watanabe Eiichi, Suzuki Atsushi, Hideo Hideo, Yuzawa Yukio, Ozaki Yukio
    CIRCULATION, 134, Nov 11, 2016  Peer-reviewed
  • Daijo Inaguma, Hibiki Shinjo, Akihito Tanaka, Eri Ito, Naoki Kamegai, Akiko Kato, Minami Mizutani, Hiroya Shimogushi, Yasuhiro Otsuka, Asami Takeda, Midori Hasegawa, Yukio Yuzawa
    CLINICAL NEPHROLOGY, 86(5) 229-235, Nov, 2016  Peer-reviewed
    Objective: To investigate the correlation between serum 1,25-dihydroxyvitamin D (1,25D) levels and left atrial diameter (LAD) using echocardiography in pre-dialysis chronic kidney disease (CKD). Subjects and methods: From an initial population of 487 patients (109 met the exclusion criteria), a total of 378 patients with CKD stage 3a - 5 who had not undergone dialysis or kidney transplantation were included in the study. The relationship between serum 1,25D levels and LAD was examined. Moreover, factors that impacted LAD were extracted through stepwise multiple regression analyses. Results: Serum 1,25D levels correlated negatively with LAD, left ventricular end-diastolic diameter, interventricular septum thickness, end-diastolic volume, stroke volume, left ventricular mass index (LVMI), and E/e'. Stepwise multiple regression analyses revealed there was a significant relationship between serum 1,25D levels and LAD (regression coefficient = -0.070, p = 0.001). In the stratified analysis, serum 1,25D levels were associated with LAD in the LVMI &lt; 125 g/m(2) (regression coefficient = -0.067, p = 0.038) and ejection fraction (EF) &gt; 60% groups (regression coefficient = -0.080, p = 0.004). Conclusion: Serum 1,25D levels were independently associated with LAD in CKD patients; however, the association was not significant in patients with an EF &lt; 60% and LVMI &gt; 125 g/m(2).
  • Ayako Kondo, Kazuo Takahashi, Tomohiro Mizuno, Akihiro Kato, Daisuke Hirano, Naoki Yamamoto, Hiroki Hayashi, Shigehisa Koide, Hiroshi Takahashi, Midori Hasegawa, Yoshiyuki Hiki, Shunji Yoshida, Keiji Miura, Yukio Yuzawa
    PLoS One, 11(10) :e0163085, Oct, 2016  Peer-reviewed
    Anti-endothelial cell antibodies (AECA) are frequently detected in patients with systemic lupus erythematosus (SLE), but their pathological role remains unclear. We recently developed a solubilized cell surface protein capture enzyme-linked immunosorbent assay (CSPELISA) to detect antibodies against membrane proteins involved in autoimmune reactions. In this study, sera from 51 patients with biopsy-proven lupus nephritis (LN), 25 with SLE without renal involvement (non-LN SLE), 42 disease control (DC) subjects, and 80 healthy control (HC) subjects were tested for IgG-and IgA-AECA for human umbilical vein endothelial cells (HUVEC) and human glomerular EC (HGEC) by using CSP-ELISA. IgG-and IgA-AECA titers were significantly higher in LN and non-LN SLE patients than in the DC or HC (P &lt; 0.001) groups. IgG-and IgA-AECA titers for HUVEC corresponded well with those for HGEC. The IgA-AECA level correlated with the SLE disease activity index and with histological evidence of active lesions (cellular proliferations, hyaline thrombi and wire loops, leukocytic infiltration, and fibrinoid necrosis) in LN patients (P &lt; 0.001). The sensitivity of IgA-AECA as a diagnostic test for histological evidence of active lesions in LN patients was 0.92, with a specificity of 0.70. The significant correlation of IgA-AECA with glomerular hypercellularity indicates that IgA-AECA are associated with endothelial damage in LN.
  • Kazunori Kawaguchi, Akira Saigusa, Shinji Yamada, Takehiro Gotoh, Shigeru Nakai, Yoshiyuki Hiki, Midori Hasegawa, Yukio Yuzawa, Nobuya Kitaguchi
    JOURNAL OF ARTIFICIAL ORGANS, 19(2) 149-158, Jun, 2016  Peer-reviewed
    The accumulation of amyloid beta protein (A beta) in the brain reflects cognitive impairment in Alzheimer's disease. We hypothesized that the rapid removal of A beta from the blood by an extracorporeal system may act as a peripheral A beta sink from the brain. The present study aimed to determine the optimal materials and modality for A beta removal by hemodialyzers. In a batch analysis, hollow-fiber fragments of polysulfone (PSf) and polymethyl methacrylate (PMMA) showed greater removal efficiency of A beta than did other materials, such as cellulose-triacetates and ethylene-vinyl alcohol copolymer (PSf: PMMA at 30 min, 98.6 +/- 2.4 %: 97.8 +/- 0.4 % for A beta(1-40) and 96.6 +/- 0.3 %: 99.0 +/- 1.0 % for A beta(1-42)). In a modality study, the A beta solution was applied to PSf dialyzers and circulated in the dialysis and Air-filled adsorption-mode (i.e., the outer space of the hollow fibers was filled with air) or phosphate-buffered saline (PBS)-filled adsorption modes. The A beta(1-40) removal efficiency of the pre/post dialyzer in the Air-filled adsorption-mode was the highest (62.4 +/- 12.6 %, p = 0.007). In a flow rate study in the Air-filled adsorption-mode, 200 mL/min showed the highest A beta(1-40) reduction rate of pool solution (97.3 +/- 0.8 % at 15 min) compared with 20 mL/min (p = 0.00001) and 50 mL/min (p = 0.00382). PMMA dialyzers showed similar high reduction rates. Thus, the optimal modality for A beta removal was the adsorption-mode with PSf or PMMA hollow fibers at around 50 mL/min flow rate, which seems to be suitable for clinical use.
  • Yoshihiro Arimura, Eri Muso, Shoichi Fujimoto, Midori Hasegawa, Shinya Kaname, Joichi Usui, Toshiko Ihara, Masaki Kobayashi, Mitsuyo Itabashi, Kiyoki Kitagawa, Junichi Hirahashi, Kenjiro Kimura, Seiichi Matsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 20(3) 322-341, Jun, 2016  Peer-reviewed
  • 大橋 篤, 中井 滋, 北口 暢哉, 比企 能之, 川口 和紀, 堀 秀生, 小出 滋久, 長谷川 みどり, 湯澤 由紀夫
    日本透析医学会雑誌, 49(Suppl.1) 657-657, May, 2016  
  • 中西 道政, 金山 恭子, 高橋 和男, 林 宏樹, 小出 滋久, 長谷川 みどり, 湯澤 由紀夫
    日本透析医学会雑誌, 49(Suppl.1) 904-904, May, 2016  Peer-reviewed

Misc.

 165
  • Toshikazu Watanabe, Tomoyuki Minezawa, Midori Hasegawa, Yasuhiro Goto, Takuya Okamura, Yosuke Sakakibara, Yoshikazu Niwa, Atsushi Kato, Masamichi Hayashi, Sumito Isogai, Masashi Kondo, Naoki Yamamoto, Naozumi Hashimoto, Kazuyoshi Imaizumi
    BMC pulmonary medicine, 19(1) 194-194, Nov 1, 2019  
    BACKGROUND: Myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis (MPO-ANCA nephritis) is occasionally accompanied by lung abnormalities such as pulmonary fibrosis. However, the clinical features of pulmonary fibrosis in patients with MPO-ANCA nephritis have not been well documented. This study was performed to compare the prognosis of a usual interstitial pneumonia (UIP) pattern of lung fibrosis in patients with MPO-ANCA nephritis with the prognosis of idiopathic pulmonary fibrosis (IPF). METHODS: We retrospectively reviewed the medical records of 126 patients with MPO-ANCA nephritis and identified 31 with a UIP pattern of lung fibrosis on high-resolution or thin-slice computed tomography (CT). We compared the characteristics and prognosis of these patients with those of 32 patients with IPF. In 18 patients from both groups, we assessed and compared the decline in lung volume over time using three-dimensional (3D) CT images reconstructed from thin-section CT data. RESULTS: The numbers of male and female patients were nearly equal among patients with MPO-ANCA nephritis exhibiting a UIP pattern; in contrast, significant male dominancy was observed among patients with IPF (p = 0.0021). Significantly fewer smokers were present among the patients with MPO-ANCA nephritis with a UIP pattern than among those with IPF (p = 0.0062). There was no significant difference in the median survival time between patients with MPO-ANCA nephritis with a UIP pattern (50.8 months) and IPF (55.8 months; p = 0.65). All patients with IPF in this cohort received antifibrotic therapy (pirfenidone or nintedanib). Almost half of the deaths that occurred in patients with MPO-ANCA nephritis with a UIP pattern were caused by non-respiratory-related events, whereas most deaths in patients with IPF were caused by respiratory failure such as acute exacerbation. In the 3D CT lung volume analyses, the rate of decline in lung volume was equivalent in both groups. CONCLUSIONS: MPO-ANCA nephritis with a UIP pattern on CT may have an unfavorable prognosis equivalent to that of IPF with a UIP pattern treated with antifibrotic agents.
  • 大山友香子, 高橋和男, 山口央輝, 松下祥子, 伊藤辰将, 中嶋和紀, 林宏樹, 小出滋久, 坪井直毅, 稲熊大城, 長谷川みどり, 湯澤由紀夫
    日本腎臓学会誌, 61(3) 287, May 15, 2019  
  • 大山友香子, 高橋和男, 山口央輝, 松下祥子, 伊藤辰将, 中嶋和紀, 林宏樹, 小出滋久, 坪井直毅, 稲熊大城, 長谷川みどり, 湯澤由紀夫
    日本腎臓学会誌, 61(3) 340, May 15, 2019  
  • 佐々木ひと美, 倉橋浩樹, 長谷川みどり, 剣持敬, 日下守, 市野学, 住友誠, 白木良一
    日本移植学会総会プログラム抄録集, 55th, 2019  
  • 佐々木ひと美, 長谷川みどり, 鈴木敦詞, 深見直彦, 市野学, 日下守, 剣持敬, 白木良一
    日本臨床腎移植学会プログラム・抄録集, 52nd, 2019  
More

Books and Other Publications

 6
More

Presentations

 268
More

Teaching Experience

 1

Professional Memberships

 11
More

Research Projects

 9
More
To the list screen